实用医学杂志 ›› 2022, Vol. 38 ›› Issue (13): 1642-1646.doi: 10.3969/j.issn.1006⁃5725.2022.13.014

• 临床研究 • 上一篇    下一篇

血清胰岛素样生长因子1在供精⁃体外受精胚胎移植黄体期长方案临床结局中的预测价值

陈潇1,2,3 崔媛媛1,2,3 谭颖1,2,3 林盛1,2,3 何毅超1,2,3 张清健1,2,3 宋革1,2,3    

  1. 1 广东省生殖医院生殖医学中心(广州510000);2 广东省生殖科学研究所生殖医学中心(广州510000); 3 国家卫生健康委男性生殖与遗传重点实验室(广州510000)

  • 出版日期:2022-07-10 发布日期:2022-07-10
  • 通讯作者: 宋革 E⁃mail:songpp@126.com
  • 基金资助:
    广东省医学科学技术研究基金资助项目(编号:B2020045)

The predictive value of IGF⁃1 in D⁃IVF taking mid⁃luteal phase GnRHa protocol

CHEN Xiao*,CUI Yu⁃ anyuan,TAN Ying,LIN Sheng,HE Yichao,ZHANG Qingjian,SONG Ge.    

  1. Reproductive center of Guangdong pro⁃ vincial Fertility HospitalGuangzhou 510000China;*Reproductive center of Guangdong provincial Reproductive Science InstituteGuangzhou 510000China;*Key Laboratory of Male Reproduction and Genetics Health Commis⁃ sionGuangzhou 510000China
  • Online:2022-07-10 Published:2022-07-10
  • Contact: SONG Ge E⁃mail:songpp@126.com

摘要:

目的 血清胰岛素样生长因子 1(IGF⁃1)在黄体期长方案体外受精胚胎移植(IVF)在临床结局中的应用价值。方法 收集本中心采用黄体中期长方案行供精⁃IVF 助孕妇女启动日和 HCG 日血清标本,分析血清 IGF⁃1 与临床结局的关系。 结果 高反应组和正常反应组启动日 IGF⁃1 无显著差异。一个 移植周期后临床妊娠组启动日 IGF⁃1 显著高于未孕组。启动日 IGF⁃1 是影响临床结局的重要因素(OR = 0.987,95%CI:0.978 ~ 0.998,P = 0.021)。启动日 IGF⁃1 预测一个移植周期临床结局的 ROC 曲线分析曲线 下面积(AUC)为 0.669(P = 0.029)。结论 采用黄体期长方案行供精⁃IVF 时,启动日 IGF⁃1 不能预测卵巢 反应,但对临床妊娠有一定预测价值。

关键词:

血清胰岛素样生长因子 1, 供精-体外受精胚胎移植, 获卵数, 正常受精数, 临床 结局

Abstract:

Objective To explore the predictive value of IGF⁃1 for ovarian response and ooctye quality in Mid⁃luteal phase GnRHa protocol. Methods Serum at the day of starting Gn therapy(Gn starting Day)and the day of HCG use(Day HCG)were collected from patients in our center taking Mid ⁃luteal phase GnRHa protocol and following Donor ⁃sperm IVF(D ⁃ IVF). And then analyzing the relationship of IGF ⁃1 and clinical outcomes. Results There was no difference of IGF⁃1 in Gn starting Day in high response and normal response Groups. IGF⁃1 in Gn starting Day was significant higher in clinical pregnant group than in nonpregnant group. IGF⁃1 in Gn starting Day was an important factor affecting clinical outcome(OR = 0.987,95%CI:0.977 ~ 0.998,P = 0.021). Receiver operator curve(ROC)for IGF⁃1 in Gn starting Day to predict clinical outcome of one transfer cycle showed that area under the curve(AUC)was 0.669(P = 0.029). Conclusions When taking Mid⁃luteal phase GnRHa protocol IGF⁃1 in Gn Starting Day cannot predict ovarian response but has predictive values for clinical pregnancy.

Key words: IGF ?1,  , D ? IVF,  , the number of retrieved oocytes,  , the number of normal fertilization,  , clinical outcomes